Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
experimental anti-anxiety drug · 1 trial · 1 indication
Hamilton Anxiety Rating Scale (HAM-A). Each of 14 symptoms categories is rated from 0=not present to 4=very severe. Numbers for all categories are summed to produce the total score. Total score ranges from 0=anxiety symptoms not present to 56=very severe anxiety symptoms across all 14 categories.
| Name | Type | Description |
|---|---|---|
| experimental anti-anxiety drug | DRUG | - |
Inclusion Criteria: * Subjects 18 to 65 years of age will be eligible to participate if they satisfy the DSM-IV-TR criteria for the diagnosis of GAD. Exclusion Criteria: * No other primary psychiatric diagnosis besides GAD.
The experimental anti-anxiety drug is being developed for the treatment of Anxiety Disorder, specifically generalized anxiety disorder. It is a small molecule being studied in the psychiatry therapeutic area. The drug is currently in Phase 3 clinical development.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is developing the experimental anti-anxiety drug. The company is conducting clinical trials for this small molecule intended to treat anxiety disorder. The drug is currently in Phase 3 development.
The experimental anti-anxiety drug is in Phase 3 clinical development. It is an investigational small molecule being studied for the treatment of anxiety disorder. The drug has completed one Phase 3 trial and is not yet approved by regulatory authorities.
The experimental anti-anxiety drug has one completed Phase 3 clinical trial, NCT00097708, titled "Experimental Medication For the Treatment of Generalized Anxiety Disorder." This trial enrolled 511 participants in the United States, with adults aged 18 years and older, and included both male and female subjects.
The experimental anti-anxiety drug is not FDA approved. It is an investigational small molecule currently in Phase 3 clinical development for the treatment of anxiety disorder. The drug has completed one Phase 3 trial but remains under investigation and has not received regulatory approval.